Chemistry i) DCC, tBuOH, CuCl; ii) HO(CH 2 ) 3 NHMe, Pd 2 (dba) 3 , BINAP, Cs 2 CO 3 ; iii) 1) MsCl, NEt 3 ; 2) 1-Boc-piperazine, KI; iv) 1) TFA/TfOH; 2) Boc 2 O, NEt 3 .
6.14 mg (19.9 µmol) tert-butyl 6-bromoquinoline-4-carboxylate, 2.56 mg (4.11 µmol) BINAP, 1.61 mg (1.76 µmol) Pd 2 (dba) 3 and 37.0 (113 µmol) cesium carbonate were dissolved in 1 mL toluene and 5.00 µL (4.95 mg; 65.9 µmol) 1,3-propanolamine were added. The mixture was stirred at 90 °C over night before solvents were removed, the residue suspended in water/acetonitrile 1:1 and filtered before µmol; 73%) of the title compound were obtained after freeze drying.
LC-MS R t 12.95 min, m/z 303.1685 [M+H] + tert-butyl 6-(3-hydroxypropylmethylamino)quinoline-4-carboxylate 99.14 mg (322 µmol) tert-butyl 6-bromoquinoline-4-carboxylate, 12.26 mg (19.7 µmol) BINAP, 7.46 mg (8.14 µmol) Pd 2 (dba) 3 and 212.85 mg (653 µmol) cesium carbonate were dissolved in 3 mL toluene and 64.0 µL (58.9 mg; 660 µmol) N-methyl-1,3-propanolamine were added. The mixture was stirred at 90 °C over night before solvents were removed, the residue suspended in water/acetonitrile 1:1 and filtered before HPLC-purification. 62.8 mg (199 µmol; 62%) of the title compound were obtained after freeze drying.
LC-MS R t 13.41 min, m/z 261.1213 [M-tBu+H] + tert-butyl 6-(3-(1-Boc-piperidin-4-yl)propyl-1-(methyl)amino)quinoline-4-carboxylate 3.12 mg (6.45 µmol; 29%) were obtained following the previous method.
LC-MS R t 19.04 min, m/z 484.3124 [M+H] + 6-(4-(4-tert-butoxypiperazin-1-yl)butyl)quinoline-4-carboxylic acid 4.75 mg (14.8 µmol) tert-butyl 6-(4-chlorobutyl)quinoline-4-carboxylate were dissolved in 200 µL trifluoroacetic acid (with 2.5% water) and shaken for 180 minutes. 1 mL dichloromethane was added and the solvents removed in vacuo, which was repeated three times. 500 µL dimethylformamide, 35.2 mg (108 µmol) cesium carbonate, 52.41 mg (282 µmol) 1-Boc-piperazine and 7.22 mg (43.5 µmol) potassium iodide were added to the residue. The mixture was shaken at 60 °C over night and purified by HPLC. 3.02 mg (7.29 µmol; 49%) were obtained after freeze drying.
LC-MS R t 10.78 min, m/z 414.2364 [M+H] + tert-butyl 6-(3-4-tert-butoxycarbonylpiperazin-1-ylpropyl-1-thio)quinoline-4-carboxylate 6.35 mg (20.6 µmol) tert-butyl 6-bromoquinoline-4-carboxylate, 2.95 mg (4.74 µmol) BINAP, 1.49 mg (1.53 µmol) Pd 2 (dba) 3 and 36.1 (111 µmol) cesium carbonate were dissolved in 2 mL toluene and 14.78 mg (48.9 µmol) 3-(4-Bocpiperazin-1-yl)-1-(acetylthio)propane were added. The mixture was stirred at 90 °C over night before solvents were removed, the residue suspended in water/acetonitrile 1:1 and filtered before HPLC-purification. 7.82 mg (16.0 µmol; 78%) of the title compound were obtained after freeze drying. tert-butyl 6-(3-(4-Boc-piperazin-1-yl)propyl-1-amino)quinoline-4-carboxylate 2.39 mg (7.91 µmol) tert-butyl 6-(3-hydroxypropylamino)quinoline-4-carboxylate were dissolved in 1 mL dichloromethane and 5.5 µL (4.02 mg; 39.8 µmol) DIPEA. 1.00 µL (1.48 mg; 12.9 µmol) methanesulfonyl chloride were added and the mixture shaken for 60 min. 53.42 mg (28.7 µmol) 1-Boc-piperazine were added before volatiles were removed. 500 µL dimethylformamide and 19.22 mg (116 µmol) potassium iodide were added to the residue. The mixture was shaken at 60 °C for 120 minutes before the product was isolated by HPLC. 3.34 mg (7.09 µmol; 90%) of the title compound were obtained after freeze drying.
LC-MS
LC-MS R t 13.54 min, m/z 471.2942 [M+H] + tert-butyl 6-(3-(4-Boc-piperazin-1-yl)propyl-1-(methyl)amino)quinoline-4-carboxylate 62.8 mg (199 µmol) tert-butyl 6-(3-hydroxypropylmethylamino)quinoline-4-carboxylate were dissolved in 5 mL dichloromethane and 90.0 µL (66.6 mg; 659 µmol) triethylamine. 20.0 µL (29.6 mg; 258 µmol) methanesulfonyl chloride were added at 0 °C and the mixture reacted for 60 min. 194.6 mg (1.05 mmol) 1-Boc-piperazine were added before volatiles were removed. 500 µL dimethylformamide and 47.4 mg (286 µmol) potassium iodide were added to the residue. The mixture was shaken at 60 °C for 120 minutes before the product was isolated by HPLC. 81.05 mg (167 µmol; 84%) of the title compound were obtained after freeze drying. 3.42 mg (12.9 µmol) of 6-(3-chloro-1-propoxy)quinoline-4-carboxylic acid, 13.3 mg (66.9 µmol) (1S,4S)-2-Boc-2,5diazabicyclo[2.2.1]heptan and 18.4 mg (111 µmol) potassium iodide were dissolved in 250 µL DMF. The reaction was shaken at 60 °C over night. The resulting suspension was diluted with 750 µL water before the product was purified by HPLC. After freeze drying 6.46 mg (11.9 µmol; 92%) of the product were obtained as the corresponding TFA-salt. 3.52 mg (7.73 µmol; 75%) were obtained following the previous method.

LC-MS R t 11.28 min, m/z 456.2478 [M+H] + 6-(3-(4-(tert-butoxycarbonylaminomethyl)-1H-1,2,3-triazol-1-yl)propoxy)quinoline-4-carboxylic acid 1.09 mg (4.01 µmol) 6-(3-azidopropoxy)quinoline-4-carboxylic acid were dissolved in 200 µL water and 1 µL (0.86 mg; 15.6 µmol) propargylamine. 1 µL saturated copper(II)acetate in water (0.36 µmol) were added and the solution was heated to 95 °C. The mixture was cooled to room temperature before 50 µL acetonitrile, 4.68 mg (21.5 µmol) di-tertbutyl dicarbonate and 5 µL (3.65 mg; 36.1 µmol) triethylamine were added. The product was isolated by HPLC after 60 min. 1.05 mg (2.45 µmol; 61%) of the title compound were obtained after freeze drying. R t 12.20 min, m/z 428.1907 [M+Na] + 6-(3-(4-(tris-tBuDOTA)piperazin-1-yl)propyl-1-thio)quinoline-4-carboxylic acid 4.73 mg (9.69 µmol) tert-butyl 6-(3-4-tert-butoxycarbonylpiperazin-1-ylpropyl-1-thio)quinoline-4-carboxylate were deprotected with 200 µL trifluoroacetic acid containing 2.5% triethylsilane and 2.5% water for 120 min. The volatiles were removed by coevaporation with dichloromethane (3×1 mL) and the residue dissolved with 100 µL dimethylformamide and 5.50 µL (4.07 mg; 31.6 µmol). Meanwhile 6.89 mg (12.0 µmol) DOTA-tris(tBu)ester and 4.69 mg (12.4 µmol) HBTU were reacted for 10 min in 150 µL dimethylformamide before addition to the deprotected quinoline solution. Finally 10.0 µL (7.40 mg; 57.4 µmol) DIPEA were added and the mixture reacted for 120 min. 6.59 mg (7.44 µmol; 77%) of the title compound were obtained after HPLC-purification and freeze-drying. 2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-Boc-piperazin-1-yl) propyl-1-thio)quinoline-4carboxamide 4.91 mg (4.65 µmol; 81%) were obtained following the previous method. N-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-Boc-piperazin-1-yl) propyl-1-amino)quinoline-4carboxamide 0.74 mg (0.71 µmol; 79%) were obtained following the previous method. 
